China Patent Granted for RECCE® Anti-Infectives
This is the final of Recce’s wholly owned patents Granted for Family 2, with the Company now patent protected in all major pharmaceutical markets globally.
The Granted Chinese Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), most notably methods of manufacture, administration and application to treat a broad range of common human infections.
China is the second largest pharmaceutical market in the world, worth approximately US$140 billion in 2021.[i] The industry has grown at an average annual rate of around 3.2% in 2023, and this growth is expected to continue due to increasing demand, healthcare reforms, and government support for pharmaceutical research and development (R).[ii]
Chief Executive Officer, James Graham said: “We thank the China National Intellectual Property Administration for their recognition of the significant potential of Recce’s New Class of Anti-infectives. We are proud to have now completed our portfolio of Family 2 Patents and now have coverage globally until at least 2035.”
Filed
Expiry
Status
China
2035
Granted
Australia
2035
Granted
USA
2035
Granted
Europe
2035
Granted
Germany
2035
Granted
Spain
2035
Granted
France
2035
Granted
UK
2035
Granted
Italy
2035
Granted
Sweden
2035
Granted
Japan
2035
Granted
This announcement has been approved for release by Recce Pharmaceuticals Board.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.
The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.
Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.
[i] Jakovljevic, M., Wu, W., Merrick, J., Cerda, A., others. (2021). Asian innovation in pharmaceutical and medical device industry–beyond tomorrow. Journal of Medical Economics.